| 1 |
35321428 | Caspase-8: Friend or Foe in Bortezomib/Lenalidomide-Based Therapy for Myeloma. | 2022 |
4 |
| 2 |
34588172 | Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide. | 2021 Dec |
5 |
| 3 |
33191863 | Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway. | 2020 Dec |
1 |
| 4 |
30845975 | The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. | 2019 Mar 7 |
1 |
| 5 |
29291406 | BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death. | 2018 Jan 29 |
1 |
| 6 |
30115673 | Bortezomib Targets Sp Transcription Factors in Cancer Cells. | 2018 Oct |
2 |
| 7 |
28972304 | DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells. | 2017 Dec |
2 |
| 8 |
27738323 | Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors. | 2016 Nov 29 |
2 |
| 9 |
25367763 | Differential impact of bortezomib on HL-60 and K562 cells. | 2015 Jan |
1 |
| 10 |
26171069 | Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. | 2015 Jul |
1 |
| 11 |
25341043 | Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. | 2014 Oct 23 |
2 |
| 12 |
24377552 | Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. | 2013 |
1 |
| 13 |
22262760 | Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. | 2012 Mar 15 |
1 |
| 14 |
22362782 | Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. | 2012 Apr 6 |
1 |
| 15 |
22408249 | Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling. | 2012 Apr 27 |
1 |
| 16 |
22739154 | [Effect of bortezomib and low concentration cytarabine on apoptosis in U937 cell line]. | 2012 Jun |
1 |
| 17 |
21755010 | Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. | 2011 |
1 |
| 18 |
20179203 | The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. | 2010 Mar 1 |
1 |
| 19 |
20442297 | Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. | 2010 May |
2 |
| 20 |
20471514 | Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. | 2010 Jun |
1 |
| 21 |
20515944 | Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. | 2010 Jun |
2 |
| 22 |
20561413 | [Effect of bortezomib on sensitization of HL-60 cells to TRAIL]. | 2010 Jun |
2 |
| 23 |
19100720 | Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. | 2009 Mar 1 |
1 |
| 24 |
19275578 | Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. | 2009 Mar |
1 |
| 25 |
20193325 | [Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin]. | 2009 Dec |
2 |
| 26 |
18221384 | Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases. | 2008 May |
1 |
| 27 |
18922907 | IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. | 2008 Oct 15 |
1 |
| 28 |
19020753 | Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma. | 2008 Dec |
1 |
| 29 |
17510429 | The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. | 2007 May 15 |
1 |
| 30 |
17620439 | TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. | 2007 Jul |
2 |
| 31 |
17786311 | The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. | 2007 Oct |
1 |
| 32 |
17897295 | M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. | 2007 Oct |
2 |
| 33 |
16528474 | JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. | 2006 Apr |
1 |
| 34 |
16733806 | Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8. | 2006 Jul |
4 |
| 35 |
15930312 | Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. | 2005 Jun 1 |
1 |
| 36 |
15070698 | The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. | 2004 Apr 15 |
2 |
| 37 |
12393500 | Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. | 2003 Feb 15 |
1 |
| 38 |
12902978 | The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. | 2003 Aug 7 |
1 |
| 39 |
12391322 | Molecular sequelae of proteasome inhibition in human multiple myeloma cells. | 2002 Oct 29 |
1 |